Tag: Takeda

Cerevance Formed Multi-Year Research Alliance with Takeda

takeda
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has formed a multi-year research alliance with Takeda Pharmaceutical to identify novel target proteins...

Takeda Announced Updated Data from Phase 3 Trial of Alunbrig versus Crizotinib

clinical-trial
Takeda Pharmaceutical Company Limited announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive (ALK...

Finch and Takeda Expanded Collaboration to Develop Microbiome-Based Therapeutics

takeda
Finch Therapeutics Group, Inc. and Takeda Pharmaceutical Company Limited announced the expansion of their collaboration to develop microbiome-based therapeutics using Finch’s Human-First Discovery® pl...

Takeda Presented Positive Results of Phase III Trial of NINLARO

Takeda Pharmaceutical Company Limited announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent...

MD Anderson Cancer Center and Takeda Announced Exclusive License Agreement to Develop CAR NK-Cell Th...

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antig...

Takeda Opened New Manufacturing Plant in Germany for Dengue Vaccine Candidate

takeda
Takeda Pharmaceutical Company Limited announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singen vaccine plant will be utilized for ...

Takeda Divested Portfolio of Select Products to STADA

takeda
Takeda Pharmaceutical Company Limited announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG, an international pharmaceutical company, for a ...

Takeda Pharmaceutical Acquired Exclusive Global License to Develop CNP-101

Takeda Pharmaceutical has signed a deal worth up to $420m with COUR Pharmaceutical Development to acquire an exclusive global license to develop and commercialise the latter’s CNP-101 (TAK-101). ...

Takeda Acquired Exclusive Global License to Develop Investigational Medicine CNP-101/TAK-101

takeda
Takeda Pharmaceutical Company Limited and COUR Pharmaceutical Development Company, Inc. announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational ...

Takeda to Sell Assets to Acino for $200m

Takeda Pharmaceutical Company Limited announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near ...

Takeda Broke into Top-20 Largest Pharmas after Shire Merger

takeda
Takeda broke into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger with Shire Pharma earlier this year, according to a new analysis using market capitalisati...

Goldfinch Bio Announced License Agreement with Takeda

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced it entered into a license ag...

Prometheus and Takeda to Discover Novel Therapies for Inflammatory Bowel Disease

Prometheus Biosciences, Inc., a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics ...

Evotec Announced Strategic Drug Discovery Collaboration with Takeda

takeda
Evotec SE announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Under the collaboration, the parties aim to establish at least five drug discovery ...

Trintellix® for Depression Treatment Approved in Japan

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S jointly announced that the MHLW of Japan approved Trintellix® (vortioxetine) for the treatment of depression and depressed state. Vortioxetine...

NICE Recommended Use of Takeda’s Takhzyro on NHS

takeda
The National Institute for Health and Clinical Excellence (NICE) - a health technology appraisal body in England and Wales - has recommended the use of Takeda’s Takhzyro (lanadelumab) on the NHS. A...